Evoke Pharma Inc. (EVOK)
4.26
0.03 (0.71%)
At close: Jan 14, 2025, 3:58 PM
4.31
1.17%
After-hours Jan 14, 2025, 03:59 PM EST
Company Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Evoke Pharma Inc.
| Country | United States |
| IPO Date | Sep 25, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Matthew J. D'Onofrio MBA |
Contact Details
Address: 420 Stevens Avenue Solana Beach, California United States | |
| Website | https://www.evokepharma.com |
Stock Details
| Ticker Symbol | EVOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001403708 |
| CUSIP Number | 30049G104 |
| ISIN Number | US30049G2030 |
| Employer ID | 20-8447886 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew J. D'Onofrio MBA | Co-Founder, Chief Executive Officer & Director |
| Mark A. Kowieski CPA | Chief Financial Officer |
| Christopher Quesenberry | Chief Commercial Officer - Gimoti (TM) |
| Dr. Marilyn R. Carlson D.M.D., M.D., RAC. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | 424B5 | Filing |
| Nov 15, 2024 | 3 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | SC 13D/A | [Amend] Filing |
| Oct 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 22, 2024 | 4 | Filing |